Medical Care Technologies, Inc. (OTC Pink:MDCE) Details Six-Phase Internal Testing Protocol Driving Melanoma Scan Beta Progress
Medical Care Technologies detailed a six-phase internal testing protocol for its MDCE Melanoma Scan Beta platform, citing results slightly above typical industry benchmarks. The AI vision models achieved sensitivity between 78-86% and specificity between 75-88% in internal validation, using datasets including the HAM10000 benchmark.
Key figures
- Drug Name
- MDCE Melanoma Scan Beta
- Phase Of Trial
- Beta / Internal Testing
- Sensitivity range
- 78-86%
- Specificity range
- 75-88%
- Melanoma cases in dataset
- 1113
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.